Welcome to our dedicated page for Merus news (Ticker: MRUS), a resource for investors and traders seeking the latest updates and insights on Merus stock.
Merus N.V. (MRUS) is a clinical-stage biotechnology company pioneering bispecific antibody therapeutics for cancer treatment through its Biclonics® platform. This page provides investors and researchers with centralized access to official announcements, clinical trial updates, and strategic developments shaping the company's trajectory in immuno-oncology.
Find timely updates on Merus' investigational therapies, including progress across multiple cancer indications. Track key milestones such as regulatory feedback, partnership expansions with pharmaceutical collaborators, and financial performance updates. Our aggregation ensures efficient monitoring of material events without promotional bias.
Content spans clinical data disclosures, research collaborations with industry leaders like Incyte and Lilly, intellectual property developments, and financial reporting. Each update is categorized for quick scanning while maintaining technical accuracy required for biotech analysis.
Bookmark this page for streamlined access to Merus' evolving story in multispecific antibody development. Combine our news repository with SEC filings and scientific publications for comprehensive investment research approach.
Merus N.V. (MRUS) announced interim results from its phase 1/2 eNRGy trial investigating zenocutuzumab (Zeno) in patients with NRG1+ cancers. As of January 12, 2021, 51 patients were treated, with 33 evaluable for response, showing 27% overall response rate (ORR) and 40% ORR in pancreatic cancer. The safety profile remains favorable, with most adverse events mild or moderate. An oral presentation of updated interim analysis is set for ASCO on June 4, and an investor call is planned for June 6 to discuss results and provide program updates.
Merus N.V. (Nasdaq: MRUS) announced new collaborations in Israel, Italy, and Spain to enhance molecular screening for patients with cancers linked to neuregulin 1 (NRG1) fusions and promote the eNRGy clinical trial for its bispecific antibody, zenocutuzumab (Zeno). Progenetics, AISP, and Universidad de Navarra will educate patients and oncologists about these screenings. This initiative aims to improve patient treatment options and potentially recruit more patients for the eNRGy trial, which evaluates Zeno's safety and efficacy in treating NRG1+ cancers.
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced that CEO Bill Lundberg will participate in a fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on May 18 at 8:00 a.m. ET. The presentation will be available via a live webcast on the company's Investors page, with an archived version accessible for a limited time afterward.
Merus specializes in developing innovative multispecific antibodies, known as Biclonics® and Triclonics®, aiming to provide advanced therapeutic options in cancer treatment.
Merus N.V. (Nasdaq: MRUS) announced its Q1 2021 financial results, showing a total revenue of $8.35 million, a significant increase from $6.30 million in Q1 2020. The operating loss was $21.79 million, up from $19.57 million year-over-year. Cash and equivalents rose to $374.4 million, bolstered by a follow-on offering and a $60 million collaboration with Lilly. Key highlights include the upcoming ASCO presentation on zenocutuzumab and the advancement of its clinical pipeline with MCLA-145 and MCLA-129 trials. Additionally, Cecile Geuijen was promoted to Chief Scientific Officer.
Merus N.V. (Nasdaq: MRUS) has commenced a phase 1/2 clinical trial for MCLA-129, a bispecific antibody targeting advanced non-small cell lung cancer (NSCLC) and other solid tumors. This trial aims to evaluate safety, tolerability, and clinical activity, focusing on determining the maximum tolerated dose. MCLA-129, developed in collaboration with Betta Pharmaceuticals, has shown promise in preclinical studies for treating EGFR-resistant NSCLC. This strategic initiative marks a significant advancement in Merus' oncology portfolio, aimed at addressing treatment resistance.
Merus N.V. (Nasdaq: MRUS) announced its selection for an oral presentation at the ASCO Annual Meeting from June 4-8, 2021. The presentation will focus on interim clinical data for zenocutuzumab (Zeno), a bispecific antibody targeting NRG1 fusion positive cancers. Currently, patients are being recruited for the phase 1/2 eNRGy trial assessing Zeno's safety and anti-tumor efficacy. The session will be led by Dr. Alison Schram from Memorial Sloan Kettering Cancer Center and will provide updated analyses on this promising candidate.
Merus N.V. (Nasdaq: MRUS) reported its financial results for Q4 and FY 2020, highlighting advancements in its clinical programs. The clinical update for zenocutuzumab is expected in 2Q 2021, focusing on NRG1 fusion cancers, with over 30 patients involved. Collaboration with Loxo Oncology has resulted in $60 million of upfront payments and equity investment. The company aims to extend its financial runway to at least 2H 2024, supported by cash reserves of $207.8 million. R&D expenses increased by $14.4 million, primarily due to escalating costs for zenocutuzumab.
Merus N.V. (Nasdaq: MRUS) has announced its participation in the AACR 2021 Annual Meeting, presenting preclinical data on its innovative multispecific antibodies, zenocutuzumab and MCLA-129. These presentations, scheduled for April 10-15 and May 17-21, 2021, will focus on the effectiveness of zenocutuzumab against tumors driven by NRG1 gene fusions and MCLA-129's role in impairing NSCLC tumor growth. The company aims to showcase the potential of its Biclonics® technology in cancer therapies.
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced that CEO Bill Lundberg, M.D., will participate in a fireside chat at the 33rd Annual Roth Conference on March 15, 2021, at 2:00 p.m. ET. The event will be accessible via a live webcast on the Company’s Investors page, with an archived version available for a limited time afterward.
Merus is known for developing innovative, full-length multispecific antibodies, branded as Biclonics® and Triclonics®, which have shown promising features in clinical studies.
On February 1, 2021, Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced that CEO Bill Lundberg will participate in upcoming investor conferences. Key events include the Guggenheim Healthcare Talks 2021 Oncology Days on February 12, LifeSci Partners Precision Oncology Day on February 17, and the 2021 SVB Leerink Global Healthcare Conference on February 26. Webcasts of the presentations will be accessible via the Company’s Investors page, with archived versions available for a limited time.
FAQ
What is the current stock price of Merus (MRUS)?
What is the market cap of Merus (MRUS)?
